Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia

• Published in: Leukemia Vol. 33; no. 8; pp. 1835 - 1850
• Main Authors: Branford, Susan, Kim, Dennis Dong Hwan, Apperley, Jane F., Eide, Christopher A., Mustjoki, Satu, Ong, S. Tiong, Nteliopoulos, Georgios, Ernst, Thomas, Chuah, Charles, Gambacorti-Passerini, Carlo, Mauro, Michael J., Druker, Brian J., Kim, Dong-Wook, Mahon, Francois-Xavier, Cortes, Jorge, Radich, Jerry P., Hochhaus, Andreas, Hughes, Timothy P.
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 01.08.2019; Nature Publishing Group
• Subjects: 631/208; 631/67; 631/67/1990/283/1896; Cancer; Cancer Research; Chronic myeloid leukemia; Classification; Critical Care Medicine; Diagnosis; Diagnostic systems; Disease control; Disease resistance; Drug development; Enzyme inhibitors; Evaluation; Genes; Genes, Neoplasm; Genetic transformation; Genomic analysis; Hematology; Hematopoiesis; Humans; Intensive; Internal Medicine; Kinases; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - etiology; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics; Management; Medicine; Medicine & Public Health; Mutants; Mutation; Myeloid leukemia; Next-generation sequencing; Oncology; Patients; Protein Kinase Inhibitors - therapeutic use; Protein-tyrosine kinase; Protein-Tyrosine Kinases - antagonists & inhibitors; Repressor Proteins - genetics; Review Article; Risk Assessment; Sequences; Transcription; Tyrosine

Outcomes for patients with chronic myeloid leukemia (CML) have substantially improved due to advances in drug development and rational treatment intervention strategies. Despite these significant advances there are still unanswered questions on patient management regarding how to more reliably predi...